Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H28O2 |
Molecular Weight | 288.4244 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@]4([H])CC(=O)CC[C@]34C
InChI
InChIKey=RAJWOBJTTGJROA-QJISAEMRSA-N
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-16H,3-11H2,1-2H3/t12-,14+,15+,16+,18+,19+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/16353603Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3783591 | https://www.ncbi.nlm.nih.gov/pubmed/12161001 | https://www.ncbi.nlm.nih.gov/pubmed/13795320
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16353603
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3783591 | https://www.ncbi.nlm.nih.gov/pubmed/12161001 | https://www.ncbi.nlm.nih.gov/pubmed/13795320
Etiocholanedione is a natural metabolite of dehydroepiandrosterone with potent antiobesity activity. Etiocholanedione has been identified as a metabolite of an altered androgen metabolism that eventually leads hepatocellular carcinoma to impaired hormone responsiveness in human. Etiocholanedione has been identified as a metabolite of 17alpha-hydroxyprogesterone in some patients affected by congenital adrenal hyperplasia, although it doesn't appear to account for the masculinization observed in congenital hyperplasia.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3783591 |
20.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16353603
4 g for 20-weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
95896
Created by
admin on Fri Dec 15 15:36:35 GMT 2023 , Edited by admin on Fri Dec 15 15:36:35 GMT 2023
|
||
|
FDA ORPHAN DRUG |
92695
Created by
admin on Fri Dec 15 15:36:35 GMT 2023 , Edited by admin on Fri Dec 15 15:36:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB07375
Created by
admin on Fri Dec 15 15:36:35 GMT 2023 , Edited by admin on Fri Dec 15 15:36:35 GMT 2023
|
PRIMARY | |||
|
16985
Created by
admin on Fri Dec 15 15:36:35 GMT 2023 , Edited by admin on Fri Dec 15 15:36:35 GMT 2023
|
PRIMARY | |||
|
213MVW2TZD
Created by
admin on Fri Dec 15 15:36:35 GMT 2023 , Edited by admin on Fri Dec 15 15:36:35 GMT 2023
|
PRIMARY | |||
|
DTXSID10153778
Created by
admin on Fri Dec 15 15:36:35 GMT 2023 , Edited by admin on Fri Dec 15 15:36:35 GMT 2023
|
PRIMARY | |||
|
440114
Created by
admin on Fri Dec 15 15:36:35 GMT 2023 , Edited by admin on Fri Dec 15 15:36:35 GMT 2023
|
PRIMARY | |||
|
Etiocholanedione
Created by
admin on Fri Dec 15 15:36:35 GMT 2023 , Edited by admin on Fri Dec 15 15:36:35 GMT 2023
|
PRIMARY | |||
|
1229-12-5
Created by
admin on Fri Dec 15 15:36:35 GMT 2023 , Edited by admin on Fri Dec 15 15:36:35 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD